EGFR and non-small cell lung carcinoma: The majority of NSCLC patient samples and cell lines harbor persistent STAT3 activation and high intra-tumoral pSTAT3 levels correlate with advanced disease stage, smoking and EGFR-mutation status [43,44,45,46,47].